1 documents found
Information × Registration Number 0119U102910, R & D request Title 26-week, multicenter, randomized, placebo-controlled, double-blind phase 3 trial in parallel groups with a 26-week extension for safety and efficacy evaluation of dapagliflozin 5 and 10 mg and saxaglintin at 2.5 and 5 mg in pediatric patients with type 2 diabetes, 10 years of age and older, who are under 18 years of age Head Kriuchko Tetiana О., Доктор медичних наук Registration Date 23-08-2019 Organization Ukrainian medical stomatological Academy popup.description1 The study of phase 3 in parallel groups with a 26-week extended period for safety reasons to evaluate the safety and efficacy of dapagliflozin at a dose of 5 and 10 mg and saxaglintin at a dose of 2.5 and 5 mg in pediatric patients with type 2 diabetes mellitus, ages 10 and older who are under 18 years of age popup.nrat_date 2024-12-10 Close
search.res_rk
26-week, multicenter, randomized, placebo-controlled, double-blind phase 3 trial in parallel groups with a 26-week extension for safety and efficacy evaluation of dapagliflozin 5 and 10 mg and saxaglintin at 2.5 and 5 mg in pediatric patients with type 2 diabetes, 10 years of age and older, who are under 18 years of age
Head: Kriuchko Tetiana О.. 26-week, multicenter, randomized, placebo-controlled, double-blind phase 3 trial in parallel groups with a 26-week extension for safety and efficacy evaluation of dapagliflozin 5 and 10 mg and saxaglintin at 2.5 and 5 mg in pediatric patients with type 2 diabetes, 10 years of age and older, who are under 18 years of age. Ukrainian medical stomatological Academy. № 0119U102910
1 documents found

Updated: 2026-03-21


Роздрукувати цю сторінку